Skip to main content

NYKD · NYKODE THERAPEUTICS ASA · Investor Relations

3.4400 NOK +0.0400 (+1.18%) At close · Oct 9
Market Cap
1.35B NOK
Shares
391.55M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-10-03 DNB Carnegie Nordic Healthcare Conference Conference
2026-09-16 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-03-10 DNB Carnegie Nordic Healthcare Conference Conference
2026-02-25 ABG Investor Presentation Presentation
2025-11-25 DNB Carnegie Nordic Healthcare Conference Conference
2025-10-09 H.C. Wainwright Global Investment Conference Conference
2025-09-10 H.C. Wainwright Global Investment Conference Conference
2025-08-27 Strategy Update & Q2 2025 Results Presentation Presentation
2024-11-08 Nykode Therapeutics VB10.NEO update – presentation Presentation
2024-08-11 Nykode Therapeutics VB10.NEO update – presentation Presentation
2024-01-10 42nd Annual J.P. Morgan Healthcare Conference, January 10, 2024 – presentation Conference
2023-12-14 DNB Nordic Healthcare Conference, December 14, 2023 – presentation Conference
2023-11-17 Jefferies Healthcare Conference, November 16, 2023 – presentation Conference
2023-09-27 Nykode Therapeutics – Capital Markets Day in Oslo on September 27, 2023 – presentation Presentation
2023-09-20 Nykode Therapeutics – Capital Markets Day in New York on September 20, 2023 – presentation Presentation
2023-09-11 H.C. Wainwright 25th Annual Global Investment Conference, September 11, 2023 – presentation Conference
2023-09-01 Nykode Therapeutics – Presentation at the 41st Annual J.P. Morgan Healthcare Conference Conference
2023-07-06 Jefferies Healthcare Conference, June 7, 2023 – presentation Conference
2023-06-07 Jefferies Healthcare Conference, June 7, 2023 – presentation Conference
2023-04-19 Nykode Therapeutics – Final Results from the Phase 2 VB-C-02 trial – presentation Presentation
2023-04-18 Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer – presentation Presentation
2023-01-09 Nykode Therapeutics – Presentation at the 41st Annual J.P. Morgan Healthcare Conference Conference
2022-12-20 Nykode Therapeutics – Clinical development plan for VB10.16 – presentation Presentation
2022-11-24 ABG oncology seminar, November 23, 2022 – presentation Presentation
2022-11-07 Credit Suisse 31st Annual Healthcare conference, 2022 – presentation Conference

Source: https://nykode.com/investors/